Braveheart Bio, Inc. (BRVE) — real insider trading activity disclosed to the SEC, tracked automatically as new Form 4 filings are reported. Most recent: Chimovits Erez — 2 open-market purchases between 2026-08-07 and 2026-08-07, totaling $34,920,000.
Transactions disclosed by company insiders to the SEC on Form 4, most recent first.
| Insider | Role | Date | Shares | Value |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director | 2026-08-07 | 9,132,420 | $0 |
| ORBIMED ADVISORS LLC | Director | 2026-08-07 | 1,666,667 | $30,000,006 |
| ORBIMED ADVISORS LLC | Director | 2026-08-07 | 273,333 | $4,919,994 |
| Chimovits Erez | Director | 2026-08-07 | 9,132,420 | $0 |
| Chimovits Erez | Director | 2026-08-07 | 1,666,667 | $30,000,006 |
| Chimovits Erez | Director | 2026-08-07 | 273,333 | $4,919,994 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Insider | 2026-08-07 | 7,420,091 | $0 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | Insider | 2026-08-07 | 9,132,420 | $0 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | Insider | 2026-08-07 | 7,990,867 | $0 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | Insider | 2026-08-07 | 1,920,000 | $34,560,000 |
Data compiled from public SEC filings. This is informational reporting, not investment advice.
A new Form 4 filing shows Erez Chimovits, a Director and 10%+ Owner of Braveheart Bio, Inc. (BRVE), purchased 1,666,667 shares on the open market on 2026-08-07 at $18.00 per share, a total outlay of $30,000,006.00. Following the purchase, Chimovits holds 11,901,826 shares indirectly, through a trust or entity structure rather than in a personal … Read more
OrbiMed Advisors LLC, a director and 10%-plus owner of Braveheart Bio, Inc. (BRVE), disclosed an open-market purchase of 1,666,667 shares at $18.00 apiece, a cash outlay of $30,000,006.00, according to a Form 4 filed with the SEC. The transaction is dated August 7, 2026, and brings OrbiMed’s indirectly held stake to 11,901,826 shares. The purchase … Read more
A new Form 4 filing shows Forbion Growth Opportunities Fund III Cooperatief U.A., listed as an insider of Braveheart Bio, Inc. (BRVE), purchased 1,920,000 shares of the company on August 7, 2026. The shares were bought on the open market at $18.00 apiece, for a total outlay of $34,560,000.00. Following the purchase, the fund’s directly … Read more